In detail, in the phase I dose expansion study (NCT02590952; PI: Yi-long Wu, Guangdong General Hospital, China) of epitinib, EGFR-mutant NSCLC patients with confirmed brain metastases who had either been previously treated with an EGFR TKI or were EGFR TKI treatment-naïve were enrolled. This evidence concerns the gene EGFR and non-small cell lung carcinoma.